Tissue Procurement Substudy for Participants in Study CP-MGA271-01

Patients with easily accessible tumors (generally, metastatic deposits involving skin,
subcutaneous tissues, or peripheral lymph node whose excision would not require general
anaesthesia or the invasion of a body cavity) at the screening visit for participation in
Study CP-MGA271-01 (the main study) will be asked to participate in this substudy. After
providing appropriate informed consent, patients will undergo excisional biopsy, punch
biopsy, or core needle biopsy of the accessible tumor prior to receiving study drug in the
main study and then again after the first cycle of study drug is completed.

Some of the biopsy tissue will be sent to a central laboratory for research purposes. The
central lab will analyze the tissue to see what effects that the study drug might have on
tumors.

Inclusion Criteria:

- Qualified, by meeting all inclusion and exclusion criteria, for participation in
Study CP-MGA271-01.

- Must have provided informed consent to participate in Study CP-MGA271-01.

- Must have accessible tumors (generally speaking, metastatic deposits involving skin,
subcutaneous tissue, or peripheral lymph node whose excision, punch biopsy, or core
needle biopsy would not require general anaesthesia or the invasion of a body
cavity).

- Willing to undergo two minor surgical procedures with no expectation of personal
benefit

- Have provided Informed Consent for this substudy as indicated by a signature on an
approved consent document obtained from the patient or his/her legally authorized
representative

Exclusion Criteria:

- Any medical condition that would contraindicate the use of local or locoregional
anaesthesia, or conscious sedation for the intended minor surgical procedure.

- Any medical condition (eg. skin disease or bleeding diathesis) that would hinder
wound healing following a minor surgical procedure.

- Dementia or altered mental status that would preclude understanding and rendering of
informed consent.